Abstract
TLC G-65, a liposome-encapsulated gentamicin, was given intravenously twice weekly for 4 weeks to AIDS patients with Mycobacterium avium-M. intracellulare complex (MAC) bacteremia at 1.7 mg of gentamicin per kg of body weight per infusion (4 patients), 3.4 mg/kg (10 patients), and 5.1 mg/kg (7 patients). MAC colony counts in blood fell by 75% or more in all three groups (P < 0.005). Drug resistance did not emerge during the study period. Transient renal insufficiency developed in one patient; no other adverse effects were detected. Liposome-encapsulated gentamicin is a potential therapy for MAC infections in AIDS patients.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase I
-
Clinical Trial, Phase II
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acquired Immunodeficiency Syndrome / complications*
-
Adult
-
Bacteremia / drug therapy*
-
Bacteremia / microbiology
-
Colony Count, Microbial
-
Drug Carriers
-
Female
-
Gentamicins / administration & dosage*
-
Gentamicins / pharmacokinetics
-
Gentamicins / therapeutic use*
-
Humans
-
Infusions, Intravenous
-
Liposomes
-
Male
-
Mycobacterium avium Complex / drug effects
-
Mycobacterium avium Complex / growth & development
-
Mycobacterium avium-intracellulare Infection / complications
-
Mycobacterium avium-intracellulare Infection / drug therapy*
-
Mycobacterium avium-intracellulare Infection / microbiology
Substances
-
Drug Carriers
-
Gentamicins
-
Liposomes